Multiple sclerosis (MS), an inflammatory disease of the central nervous system, is characterized by progressive neuronal loss and worsening physical disability. Although there are a number of currently marketed therapies that target the immune component of MS, including interferon-beta (IFN-beta) therapy and Teva Copaxone (glatiramer acetate), few available drugs are able to reduce or reverse disability progression. There is great opportunity for emerging agents that are neuroprotective, as well as for therapies that offer greater convenience and improved quality of life for MS patients.
Using tiering and restrictions data from Fingertip Formulary, as well as insight from 51 pharmacy directors, this report determines the key trends in reimbursement of MS treatments, drivers of these trends, and how stakeholders can capitalize on future shifts in coverage to steal share from the competition and provides insight for stakeholders looking to capitalize on future shifts in coverage in order to better position their products among competitors.